Halozyme Therapeutics | HALO - Assets



Halozyme Therapeutics reported $2.05B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
Acadia Pharmaceuticals USD 1.23B 93.19M Jun/2025
Agios Pharmaceuticals USD 1.47B 84.28M Jun/2025
Alnylam Pharmaceuticals USD 4.57B 352.21M Jun/2025
Amarin USD 655.68M 29.67M Mar/2025
Amgen USD 87.9B 1.47B Jun/2025
Baxter International USD 21.3B 4.48B Mar/2025
Cytokinetics USD 1.23B 38.42M Jun/2025
DBV Technologies USD 143.43M 92.87M Jun/2025
Eli Lilly USD 100.92B 11.53B Jun/2025
Halozyme Therapeutics USD 2.05B 142.63M Jun/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
MannKind USD 411.7M 1.56M Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
United Therapeutics USD 7.91B 164.1M Jun/2025